Merck & Co. Inc., of Whitehouse Station, N.J., said it inked an agreement with the Medicines Patent Pool (MPP) to license its pediatric formulations of raltegravir for use in treating HIV-1 infection in infants and children, ages 4 weeks to younger than 12 years, in developing countries.